Consistent with the in vitro results, we found that NLRP6 overexpression promoted glioma progression (Fig. 5h), while NLRP6 deficiency inhibited tumour growth in vivo (Supplementary Fig. 6q). Here, NLRP6 is linked to central nervous system cancer.